Raymond James Financial Inc. Buys Shares of 109,317 Takeda Pharmaceutical Company Limited (NYSE:TAK)

Raymond James Financial Inc. purchased a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 109,317 shares of the company's stock, valued at approximately $1,447,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Assetmark Inc. grew its stake in shares of Takeda Pharmaceutical by 6.4% during the 4th quarter. Assetmark Inc. now owns 86,167 shares of the company's stock worth $1,141,000 after purchasing an additional 5,185 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Takeda Pharmaceutical by 35.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 253,551 shares of the company's stock valued at $3,357,000 after buying an additional 66,386 shares in the last quarter. Schechter Investment Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 2.5% during the 4th quarter. Schechter Investment Advisors LLC now owns 119,668 shares of the company's stock valued at $1,584,000 after acquiring an additional 2,884 shares during the period. Sage Rhino Capital LLC boosted its stake in shares of Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after acquiring an additional 1,538 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Takeda Pharmaceutical by 389.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 10,020 shares of the company's stock worth $132,000 after acquiring an additional 7,972 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Remove Ads

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.45 on Friday, hitting $14.74. The company's stock had a trading volume of 4,265,491 shares, compared to its average volume of 1,817,303. The company has a market capitalization of $46.89 billion, a P/E ratio of 36.84, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.37. The firm has a fifty day moving average price of $14.32 and a 200-day moving average price of $13.93. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.